Published February 2018. VacZine Analytics' commercial intelligence on opioid use disorder vaccines is available in VAMV078 - MarketVIEW: Opioid Use Disorder (OUD) Vaccines.
The OUD Epidemic
Opioid use disorder (OUD) is a chronic relapsing condition characterised by a problematic pattern of heavy, uncontrolled opioid use. In the United States, OUD typically involves consumption of licensed prescription painkillers such as oxycodone and hydrocodone, or illicit street drugs such as heroin and synthetic analogues including fentanyl. In 2015, approximately 2.1 million and 0.59 million individuals had OUD associated with prescription painkillers and heroin respectively (CDC figures, self-reported). Past-year use numbers were as high as 13-15 million people in the US.
US opioid overdose deaths in 2016 - the highest on record at the time of publication. OUD was lowering the life expectancy of the average American and costing the economy billions in direct and indirect costs.
Why a Vaccine?
Medication-assisted therapy (MAT) involving methadone, buprenorphine, and naltrexone, in combination with psychosocial counselling, can stabilise the opioid user through detoxification or maintenance strategies. However, these treatments carry significant safety considerations and are associated with high relapse or discontinuation rates. Moreover, only a fraction of opioid users initiate therapy. New interventions are desperately needed.
Opioid hapten-based conjugate vaccine technologies have shown promising effects in preclinical models. An ideal OUD vaccine should be broad-spectrum and multivalent, blocking both the addictive and toxic effects of opioids, thereby decreasing patient relapse - possibly in combination with existing therapies. An OUD vaccine could be safer, have a longer efficacy duration, and result in better compliance than existing small-molecule therapies. Simplicity and a lower perceived stigma might also drive more people into treatment programmes.
"Even with the most conservative assumptions, from a commercial perspective, there is certainly enough incentive for manufacturers to get involved. Revenues would be sufficient to recoup investment and, most importantly, they appear sustainable." - John Savopoulos, Director of Research & Analysis
Addressing the Sceptics
Some commentators noted that an OUD vaccine would not be a "magic bullet" and would take too long to develop - concerns that could dissuade large company involvement. In response, Savopoulos stated: "If you look at illicit opioid production and supply on a global level there are no signs that this problem will go away, even if we curb prescriptions in the United States. This is a chronic global issue and no different to other relapsing health conditions that receive far more attention. Of course, we need an aggressive multi-pronged approach, but the more tools we have the better. Innovation always takes time."
The new VacZine Analytics MarketVIEW study (VAMV078) consists of a detailed executive presentation (~140 slides) and a comprehensive MS-Excel workbook forecasting the potential commercial value and volume of a putative OUD vaccine across 8 major western markets from 2030. Three scenarios are modelled, exploring vaccine uptake at various access points along the patient treatment continuum.
This article is available in VacZine Analytics' Expert News archive as published in February 2018. For current intelligence on OUD vaccines, see VAMV078.